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Abstract
Acquired demyelinating disorders of central nervous system (CNS) are rare disorders in the pediatric age group and are characterized 
by demyelination occurring at various sites in the nervous system. Demyelination can involve an isolated CNS site such as brain, spinal 
cord (transverse myelitis) and optic nerves (optic neuritis) or can involve multiple areas of the nervous system. This group of disorders 
includes transient single-time events like acute demyelinating encephalomyelitis (ADEM) to life-long conditions like multiple sclerosis 
(MS). Repeated acute episodes of demyelination may be a harbinger to the development of chronic demyelinating disorders. Early and 
accurate distinction between transient acute single-time demyelinating events and chronic relapsing conditions like MS is of paramount 
importance as treatment protocols and prognosis are widely different. Early disease modifying therapy may be beneficial in MS to 
suppress the ongoing and future relapses, whereas in ADEM, only short-term steroid therapy is all that is needed with an overall good 
prognosis.
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Acquired demyelinating disorders are characterized by demyelination occurring at various sites in the nervous system varying from an isolated central 
nervous system (CNS) site such as brain, spinal cord 
and optic nerves to multiple areas of the nervous system. 
Repeated acute episodes of demyelination may lead to chronic 
demyelinating disorders [1-5]. Early and accurate distinction 
between transient acute single-time demyelinating events like 
acute demyelinating encephalomyelitis (ADEM) and chronic 
relapsing conditions like multiple sclerosis (MS) is paramount 
importance as treatment protocols and prognosis are widely 
different [6-10]. Till a few years back, the term ADEM was being 
used to encompass all the clinical events involving acute focal 
neurologic deficits along with the features of demyelination on 
neuroimaging [11-14]. On the contrary, the diagnosis of MS 
was made if there were recurrent focal neurodeficits along with 
accrual of demyelinating lesions on neuroimaging that were 
separated in time and space [1,2,15-18].
This classification was marred by description of various 
new entities and varying natural histories of the demyelinating 
disorders [1-3,7]. Hence, it was thought that clinical, biologic, 
and radiographic delineation of the various monophasic 
and chronic childhood demyelinating disorders requires an 
operational classification system to facilitate the prospective 
research studies. Extensive literature review led International 
Pediatric MS Study Group (IPMSG) to formulate an operational 
classification of acquired demyelinating disorders so as to be 
able to interpret the future studies better [1-3]. This classification 
system has taken into account clinical presentation, recurrence, 
and neuroimaging features.
PATHOLOGY OF DEMYELINATING DISORDER
The pathological hallmark of ADEM is perivenular 
inflammation with limited sleeves of demyelination [19]. In 
some cases, large areas of demyelination occurs secondary to 
coalescence of many perivenous demyelinating lesions. Acute 
hemorrhagic leucoencephalitis is pathologically similar to 
ADEM, but additionally exhibits the petechial hemorrhages and 
venular necrosis. In MS also, though perivascular inflammation 
occurs, more prominent are confluent sheets of macrophage 
infiltration admixed with reactive astrocytes in completely 
demyelinated regions. These pathological differences suggest 
that brain histopathology could be a possible diagnostic gold 
standard and may be clinically useful to differentiate between 
ADEM and MS. However, the true utility of brain biopsy in 
distinguishing ADEM, MS and other idiopathic demyelinating 
disorder has not been examined so far [19].
EPIDEMIOLOGY
There are no clear studies of worldwide distribution of acquired 
demyelinating disorders of childhood. Incidence of these disorders 
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remains unidentified in our country due to lack of specific 
diagnosis, inadequate data and follow-up. Mean incidence of 
ADEM was estimated to be 0.4/1,00,000/year among persons 
<20 years of age [14]. Whereas ADEM is a disease of children 
and young adults with mean age at presentation ranging between 
5 and 8 years in different studies [12,20], MS is considered to be 
a disease of young adults with mean age of onset 30 years and it 
is becoming increasingly recognized that MS affects children and 
adolescents prior to 18 years [7]. MS is twice more common in 
females as described in different studies [1,4,7]; whereas, ADEM 
has been described more frequently in boys with a female to male 
ratio of 0.6-0.8 [21]. There is little data in literature regarding 
the incidence of other demyelinating disorders like transverse 
myelitis (TM), optic neuritis (ON), neuromyelitis optica (NMO) 
and polyfocal demyelination. Recently in a prospective study 
from UK, incidence of acute transverse myelopathy in children 
under 16 years is at least 1.72 per million children per year [22].
There were multiple predisposing factors identified due to 
temporal and occasionally causal relationship in some reported 
case series, none of them is causative. Some of them are preceding 
viral infections, vaccination mainly influenza, varicella and 
measles. There are some case reports that have demyelination 
features with rabies and some viral diarrhea [2,3,23].
IPMSG CLASSIFICATION AND DEFINITION [2,3]
Clinically Isolated Syndrome (CIS)
•	 A	 monofocal	 or	 polyfocal,	 clinical	 CNS	 event	 with	
presumed inflammatory demyelinating cause
•	 Absence	of	a	prior	clinical	history	of	demyelinating	disease	
(e.g., ON, TM and hemispheric or brain-stem related 
syndromes)
•	 No	encephalopathy	that	cannot	be	explained	by	fever
•	 The	diagnosis	of	MS	based	on	baseline	magnetic	resonance	
imaging (MRI) features is not met.
ADEM (Monophasic)
•	 First	 clinical	 event	 with	 presumed	 inflammatory	 or	
demyelinating cause, with acute or subacute onset 
that affects multifocal areas of the CNS. The clinical 
presentation must be polysymptomatic and must include 
encephalopathy (i.e., behavioral changes e.g., confusion, 
excessive irritability and/or alternation in consciousness 
e.g. lethargy, coma)
•	 Event	should	be	followed	by	improvement	either	clinically	
on MRI or both, but there may be residual deficits
•	 No	 history	 of	 a	 clinical	 episode	with	 features	 of	 a	 prior	
demyelinating event
•	 No	other	etiologies	can	explain	the	event
•	 New	 or	 fluctuating	 symptoms,	 signs,	 or	 MRI	 findings	
occurring within 3 months of the inciting ADEM event are 
considered part of the acute event
•	 Neuroimaging	 shows	 focal	 or	 multifocal	 lesion(s),	
predominantly involving white matter, without radiologic 
evidence of previous destructive white matter changes
	 •	 	Brain	MRI,	with	 fluid-attenuated	 inversion	 recovery	
(FLAIR)	or	T2-weighted	images,	reveals	large	(1-2	cm	
in size) lesions that are multifocal, hyperintense, and 
located in the supratentorial or infratentorial white 
matter regions; grey matter, especially basal ganglia 
and thalamus, is frequently involved
	 •	 	In	rare	cases,	brain	MRI	shows	a	large	(1-2	cm)	single	
white matter lesion
	 •	 	Spinal	cord	MRI	may	show	confluent	intramedullary	
lesion(s) with variable enhancement, in addition to 
abnormal brain MRI findings above specified.
Recurrent ADEM (Obsolete Terminology as per IPMSG 
2012)
•	 New	 event	 of	 ADEM	 with	 a	 recurrence	 of	 the	 initial	
symptoms and signs, 3 or more months after the first ADEM 
event, without involvement of new clinical areas by history, 
examination, or neuroimaging. Event does not occur while on 
steroids, and occurs at least 1 month after completing therapy
•	 MRI	 shows	 no	 new	 lesions;	 original	 lesions	might	 have	
enlarged
•	 No	better	explanation	exists
•	 Due	to	very	low	frequency	of	its	occurrence	(1.7-3.8%)	in	
subsequent episodes after ADEM, the category of recurrent 
ADEM has been eliminated form 2012 IPMSG consensus 
definition [2].
Multiphasic ADEM
•	 ADEM	 followed	 by	 a	 new	 clinical	 event	 also	 meeting	
criteria for ADEM, but involving new anatomic areas of 
the CNS as confirmed by history, neurologic examination, 
and neuroimaging
•	 The	subsequent	event	must	occur	at	 least	3	months	after	
the onset of the initial event
•	 Presentation	at	subsequent	event	must	be	polysymptomatic	
including encephalopathy, with neurologic symptoms or 
signs that may differ or remained same as the initial event
•	 The	 second	 ADEM	 event	 can	 involve	 either	 new	 or	 a	
re-emergence of prior neurologic symptoms, signs and 
MRI findings.
NMO or ADEM as First Manifestation of NMO [2]
•	 Must	have	ON	and	acute	myelitis	as	major	criteria
•	 Must	have	either	a	spinal	MRI	lesion	extending	over	three	
or more segments or be NMO positive on antibody testing
•	 Brain	MRI	not	meeting	criteria	for	pediatric	MS
•	 Pediatric	ADEM	can	also	lead	to	a	subsequent	diagnosis	of	
NMO. A positive anti-aquaporin-4 IgG titre during ADEM 
greatly facilitates this diagnosis [2].
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Pediatric MS (Any of the Following) [2]
•	 Two	or	more	 nonencephalopathic	 (e.g.,	 not	ADEM	 like)	
clinical CNS events with presumed inflammatory cause, 
separated by more than 30 days and involving more than 
one area of the CNS
•	 One	nonencephalopathic	episode	typical	of	MS	associated	
with MRI findings consistent with 2010 Revised 
McDonald criteria for dissemination in space (DIS) and in 
which a follow-up MRI shows at least one new enhancing 
or nonenhancing lesion consistent with dissemination in 
time (DIT) MS criteria [18]
•	 One	 ADEM	 attack	 followed	 by	 a	 nonencephalopathic	
clinical event, 3 or more months after symptom onset, 
that is associated with new MRI lesions that fulfil 2010 
Revised McDonald DIS criteria [18]
•	 First,	single,	acute	event	that	does	not	meet	ADEM	criteria	
and whose MRI findings are consistent with the 2010 
Revised McDonald criteria for DIS and DIT (applies only 
to	children	≥12	years	old)	[24].
Diagnosis
Diagnosis of these disorders is primarily clinico-radiological. 
There are no biological or pathological markers available for the 
diagnosis of different demyelinating disorders [2,3,17]. Clinical 
features depend on the site of demyelination and can present with 
visual loss, pyramidal signs, cerebellar signs, encephalopathy, 
and bladder-bowel dysfunction. Radiological diagnosis is based 
on demonstration of demyelinating lesions on MRI.
Clinical Evaluation
Fever	has	been	a	frequently	and	commonly	associated	finding	
with ADEM [20,25]. Most of these episodes were preceded 
by viral prodromal illnesses. Motor weakness as unilateral or 
bilateral pyramidal signs was seen in two third of patients at 
first demyelinating episode [26]. Involvement of all four limbs 
is seen more frequently with TM. Multifocal involvement is the 
hallmark of ADEM. Sensory symptoms are less pronounced 
and parasthesias, numbness and pain are mainly associated 
with TM. Complete loss of sensory function below the level of 
cord involvement is common with TM. Sensory involvement is 
infrequent in ADEM and MS [4].
Seizures can be presenting symptoms if cortical grey matter 
is involved. Most of them had generalized tonic clonic seizures 
with occurrence of status epilepticus in some patients [21,25]. 
Encephalopathy presenting as altered consciousness ranging 
from irritability to unconsciousness. Cranial nerve involvement 
is also not uncommon specifically with ADEM and MS. 
Diminution or complete loss of vision can be the presenting 
complaints with ON, ADEM, MS and NMO. It is seen more 
frequently in MS patients than ADEM patients. In patient with 
TM always search for the involvement of vision and vice versa.
Bowel	and	bladder	 involvement	 is	 seen	 in	TM	and	NMO	
while it is less common in ADEM and MS. Other clinical 
symptoms and signs as aphasia and extra-pyramidal signs 
(involvement of deep grey matter nuclei) are less common in 
ADEM patients [21,25,27]. Spinal cord involvement can be seen 
as an isolated illness TM or it can be seen in association with 
MS and ADEM; although, it is uncommon. When compared 
with patients who are eventually diagnosed to have MS, certain 
clinical characteristics are more frequent in patients with ADEM 
e.g., encephalopathy, seizures, fever, headache and meningeal 
signs [11,27]. Polysymptomatic presentation is more common 
in ADEM than MS where monosymtomatic presentation such 
as CIS, ON, TM or NMO is more common [2-4,19].
Detailed neurological examination is important for 
making a diagnosis. Glass glow Coma Score is important as 
encephalopathy is the diagnostic criteria for ADEM. Presence 
of any abnormal posturing or movements and cranial nerve 
involvement mainly 2nd, 6th, 7th, 9th and 10th should be looked 
for. Detailed motor examination (including bulk of muscles, 
tone, power, co-ordination and reflexes), sensory examination 
(peripheral and central sensory examination) as well as 
examination for the cerebellar function are also important. 
Meningeal signs have been described more frequently in 
ADEM than in MS patients [21,25]. Other things to be seen are 
hypertension, aphasia and features of raised ICP etc.
Investigations
MRI brain and spine
MRI plays a pivotal role in confirming the presence of 
CNS lesions consistent with inflammatory demyelination 
and to exclude other CNS disorders [1-3,17,28,29]. MRI 
abnormalities in ADEM include as patchy poorly marginated 
areas	of	increased	signal	intensity	on	T2	and	FLAIR	sequences.	
These lesions are usually large, multiple and asymmetric. They 
typically involve subcortical and central white matter and 
cortical	 grey-white	 matter	 junction	 of	 cerebral	 hemispheres,	
cerebellum, brainstem, and spinal cord. Periventricular and 
corpus callosal lesions are rare but their presence favors the 
diagnosis of MS over ADEM [18,30,32] (Figs. 1 and 2).
Deep grey matter nuclei involvement, commonly as thalamus 
and basal ganglia involvement, is more frequent in ADEM than 
MS [26] and it could be unilateral or bilateral. MRI criteria of 
MS have not been standardized in children yet [17,18,24,31]. 
McDonald’s criteria were approved to be used in children 
more than 10 years [2,3,31]. Main diagnostic criteria are 
dissemination of lesions in both space and over time [17,31]. 
Gadolinium contrast enhancement is more prominently seen 
in acute phase. It could be transient or of different forms like 
complete or incomplete ring, disc etc. [4,20,21]. Spinal cord 
involvement	 in	TM	may	show	T2	signal	 abnormalities.	Both	
cervical and thoracic region involved; however, number of 
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vertebral segments involved and gadolinium enhancement of 
the lesion varies [33]. Optic cuts of MRI are very important to 
rule out ON [34,35].
Identification of first episode of demyelination as MS or 
ADEM is difficult radiologically. One study by KIDMUS 
group [36] had suggested that periventricular lesions are more 
frequent in MS and number of total lesions did not differentiate 
ADEM	 from	MS.	These	 criteria	 had	 sensitivity	 of	 81%	 and	
specificity	of	95%	to	distinguish	MS	from	monophonic	ADEM	
at the time of first episode of demyelination [36].
There is no role of other modality of imaging such as MR 
spectroscopy. A recent study showed that the presence of some 
halo lesions (hypointense lesions in MRI) as more predictor of MS 
than ADEM on follow-up, but this requires long term follow-up.
Presence of at least 2 of following 4 criteria for DIS [18] 
on	MRI	(T2	and	FLAIR)	increases	the	likelihood	of	diagnosis	
of pediatric MS. Among children 12 years and older they have 
a	 positive	 predictive	 value	 of	 76%	and	 a	 negative	 predictive	
value	of	100%	[24,29,31].
(1)	 ≥1	 periventricular	 lesions	 (2)	 ≥1	 juxtacortical	 lesions	
(3)	≥1	Infratentorial	lesions	(4)	≥1	spinal	cord	lesions.
Cerebrospinal fluid (CSF) examination
Before	making	a	diagnosis	of	demyelinating	episode,	infection	
must	be	excluded	by	CSF	analysis	and	culture.	In	ADEM,	CSF	
may be normal or show a lymphocytic pleocytosis in contrast 
to	 patients	with	MS,	who	 rarely	 have	 CSF	 pleocytosis	 [19].	
Detection	of	CSF	oligoclonal	bands	may	be	useful	in	diagnosis	
Figure 1: Magnetic resonance imaging (MRI) brain and spine of patient with multiple sclerosis (MS). (a) Fluid-attenuated 
inversion recovery sequence showing periventricular asymmetrical diffuse hyperintensities. (b) MRI spine T2-weighted sequence 
showing extensive cervical and thoracic hyperintensities (This patient was diagnosed MS)
ba
Figure 2: Magnetic resonance imaging brain of patient with acute demyelinating encephalomyelitis (ADEM) showing extensive 
hyperintensities in fluid-attenuated inversion recovery sequence. (a) Extensive hyperintensities involving periventricular white 
and deep grey matter involvement including thalamus and basal ganglia. (b) Diffuse white and grey matter involvement which 
is asymmetrical (these patients diagnosed as ADEM)
ba
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of MS [4,26]. Oligoclonal bands have been shown to develop 
over the course of the disease and may be absent in early stages 
or	in	younger	patients	[4,19].	CSF	should	be	screened	for	NMO	
antibodies if suspicion of NMO is high [37,38].
Other investigations
Other investigations which have been found to support the 
diagnosis are visual evoked potentials (VEP), brainstem 
auditory	 evoked	 potentials	 (BERA),	 electroencephalogram	
(EEG) and somatosensory evoked potentials. Evoked potential 
testing can confirm the involvement or detect clinically silent 
deficits in visual, auditory or somato-sensory pathways. Anti-
thyroid peroxidase antibodies, anti-N-methyl D-aspartate 
(NMDA) antibodies etc. [39] are helpful to exclude some rare 
causes of demyelinating disorders. There are some multisystem 
disorders which involves CNS causing demyelination such 
hemophagocytic	 lymphohistiocytosis	 (HLH),	 systemic	 lupus	
erythematosus	 (SLE),	 malignancy,	 viral	 infections	 and	 they	
require specific diagnostic test for particular disease like bone 
marrow aspiration, polymerase chain reaction, biopsy etc. [39].
Differential Diagnosis [30,39]
Demyelination is a physiological diagnosis and identifying 
etiological cause is useful in some disorder for which definitive 
treatment	 is	available	 like	viral	 infection,	SLE	etc.	However,	
the diagnosis of demyelination can be made purely on clinic-
radiological basis (Fig. 3), e.g., a patient with unilateral eye 
symptoms had bilateral demyelination of optic nerve on MRI 
will be unilateral ON and not bilateral ON. There are multiple 
differential diagnoses which include:
•	 CNS	 infections:	 Neurobrucelosis,	 herpes	 simplex	
encephalitis, HIV, neurocysticercosis, Post streptococcal 
infection, abscess.
•	 Vascular	disorders:	CADASIL,	Moyamoya	disease,	carotid	
dissection
•	 Mitochondrial:	MERRF,	MELAS,	LHON
•	 Inflammatory:	 SLE,	 neurosarcoidosis,	 antiphospholipid	
antibody Syndrome, CNS vasculitis
•	 Leukodystrophy:	 Metachromatic	 leukodystrophy,	
adrenoleukodystrophy
•	 Genetic/metabolic:	 Inborn	 errors	 of	 metabolism,	 amino	
acidurias
•	 Immunogenetic	 and	 antibody	 mediated	 disease:	 these	
are relatively rare includes Hashimotos encephalopathy, 
Familial	HLH,	anti-NMDA	receptor	antibody	encephalitis
•	 Nutritional:	B12	or	folate	deficiency
•	 Neoplastic:	Lymphoma,	astrocytoma.
Treatment
Treatment includes initial stabilization of airway, breathing, 
and circulation. If raised intracranial pressure is suspected, it 
should be managed by keeping head in midline and head end 
elevation position, sedation, osmotic therapy and maintenance 
of cerebral perfusion pressure >60 mm-Hg. Abortion of 
seizures should be achieved by antiepileptic drugs. Other 
supportive management includes physiotherapy for prevention 
of contracture, occupational therapy and good nursing support 
along with psychological or psychiatric management (Fig. 4).
SPECIFIC MANAGEMENT
The corticosteroids form the mainstay of treatment in almost 
all demyelinating disorders as basic pathology is inflammation 
and autoimmunity. There are no controlled studies to document 
the efficacy of corticosteroids in ADEM [27]. However, 
corticosteroids have become the mainstay of therapy in acute 
episode of demyelination because of significant improvement 
seen	in	majority	of	cases	[9,10].	Intravenous	steroids,	preferably	
methylprednisolone or dexamethasone, can be used in acute 
episode. IV methylprednisolone at the dose of 10-30 mg/kg/day 
for 3-5 days has been recommended followed by 4-6 weeks 
of oral corticosteroids. Though, there were no RCT between 
dexamethasone and methylprednisolone, methylprednisolone 
was found to be better as compared to dexamethasone. There 
is no consensus about the dose of dexamethasone and different 
studies tried dose from 1-2 mg/kg (maximum of 16 mg/day). 
Similarly, there is no consensus about the follow-up treatment 
with steroids, but some institutional follow-up suggest better 
results with 4-6 weeks steroid therapy [25].
There is no role of immuno-modulatory therapy in 
demyelinating disorders in pediatric population. Some 
experimental treatments available are plasmapheresis and 
intravenous immunoglobulins, whereas intravenous and 
intraventricular interferon has been tried in MS. These modes 
of therapy are still experimental and need further research. 
For	adult	patients	with	MS,	there	are	10	approved	MS	DMTs	
with varying degrees of efficacy for reducing relapse risk and 
preserving neurological function, but their long-term benefits 
remain unclear. Some of them are interferon-beta, glatiramer 
acetate, mitoxantrone, natalizumab, fingolimod, teriflunomide, 
dimethyl	 fumarate,	 BG-12,	 alemtuzumab,	 rituximab,	
ocrelizumab, daclizumab [39].
Outcome
In treated patients, rapid clinical improvement has been seen 
within hours; although, complete recovery may evolve over 
days. More often, severely affected children require weeks 
or months to improve [27]. The most common sequelae seen 
following ADEM are focal motor deficits ranging from mild 
clumsiness	and	ataxia	to	hemiparesis	or	blindness.	Behavioral	
and	 cognitive	 problems	 in	 patients	 are	 not	 uncommon.	 Less	
frequent late effects include development of seizures. Though 
death is possible in acute course of the illness, most of the studies 
do not mention death as a consequence of acute demyelinating 
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illness [27]. Physical sequelae and seizures have been found 
more frequently in patients of MS.
10%	 of	 children	 with	 an	 initial	 diagnosis	 of	 ADEM	
experience another ADEM attack (with encephalopathy), 
typically occurring in the first 2-8 years after the initial 
illness [21]. The MRI lesions seen in acute phase of ADEM often 
resolve slowly over a period of few months without appearance 
of new lesions [1-3] and new lesions generally do not appear 
unles s a clinical relapse has occurred [5,21,40-42]. The finding 
of new lesions on follow-up MRI is highly suggestive of MS. 
Mikaeloff	 in	 his	 study	 found	 that	 14-20%	 of	 ADEM	 may	
evolve as MS but, the natural history of these disorders is so 
varied that it is very difficult to state the evolution of ADEM 
to MS. Therefore, prolonged follow-up clinically as well as 
radiologically is required.
In TM, patients usually have motor, sensory and sphincter 
disturbances	 [33].	Factors	 associated	with	 a	 better	 functional	
outcome include older age at the time of diagnosis, shorter 
time to diagnosis, lower sensory and anatomic levels of spinal 
injury,	 absence	 of	 T1	 hypointensity	 on	 spinal	 MRI	 during	
acute	period,	lack	of	leukocytes	in	CSF,	and	fewer	number	of	
affected spinal cord segments [43]. In ON, visual prognosis is 
perceived as satisfactory in children, especially young patients 
with bilateral disease; although, unilateral ON has also been 
reported to have better or similar visual prognosis [34,44-46]. 
The role of treatment in prognosis of ON is controversial [47].
Follow-up
Follow-up	involve	as	clinical,	radiological	and	electrophysiological	
consideration. Clinical follow-up involve detailed neurological 
examination, presence of neurodeficits and functional status. All 
patients with demyelinating lesions in the brain or spinal cord 
should undergo repeat MRI brain and spine at the end of 3 months 
to see for the residual lesions and appearance of any new lesion. 
This duration is suggested by the recent IPMSG consensus 
definition which states the evolution and characterization of these 
diseases with time duration of 3 months. The appearances of new 
lesions within 3 months are considered part of same episode while 
appearances after that time duration prompt for second episode 
or recurrence. Usual follow-up with occupational therapist and 
physiotherapist	is	very	important.	VEP,	BERA	and	EEG	during	
the follow-up should be done if indicated if new symptoms arises 
or for follow-up of previous insult.
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Figure 3: Classification of acquired demyelinating disorders of central nervous system
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